Investors revolt over pay, while BlackRock blames ‘vague’ language for underwhelming climate vote at Barclays

Round up: the latest on ESG-related resolutions

Both ISS and Glass Lewis are opposing AstraZeneca’s proposed pay package for its CEO Pascal Soriot, which, if approved, would see his potential pay soar to 900% of his reported £1.3m salary, depending on performance targets. 

It is the second year in a row that the UK-based pharma…

You must have a SUBSCRIPTION or FREE TRIAL to view this PAID content.

Already got a Subscription or Free Trial?

Login here.

Not got a Subscription or Free Trial?

Sign up for a Free Trial here to access this PAID content.

One Free Trial per user; if your Free Trial has expired, please email subs@responsible-investor.com.

Copyright © 2021 RGM.